/

Insilico Medicine

  • What it is:Insilico Medicine is a global clinical-stage biotechnology company powered by generative AI that connects biology, chemistry, and clinical trials analysis using its Pharma.AI platform to accelerate drug discovery for diseases like cancer, fibrosis, and aging-related conditions.
  • Best for:Large pharmaceutical companies, Oncology R&D teams, Companies seeking novel targets
  • Pricing:Starting from Custom enterprise contract
  • Rating:88/100Very Good
  • Expert's conclusion:Insilico Medicine will be best for large, established pharmaceutical organizations with the necessary experience and resources for using the Cloud for the purpose of being able to take advantage of an AI native drug discovery platform which will enable them to significantly decrease their drug discovery timelines and produce substantially larger numbers of new compounds than before.
Visit website
Reviewed byMaxim Manylov·Web3 Engineer & Serial Founder

What Is Insilico Medicine and What Does It Do?

Insilico Medicine is a biotech firm that uses generative AI, deep learning, and big data analysis to conduct end-to-end drug discovery and development (targeting various disease areas such as cancer, fibrosis, immunology, CNS disorders and age-related diseases) through the use of its Pharma.AI platform. The company has moved several AI-designed drugs into clinical trials.

Active
📍Boston, MA
📅Founded 2014
🏢Private
TARGET SEGMENTS
Pharmaceutical CompaniesBiotechnology FirmsHealthcare Institutions

What Are Insilico Medicine's Key Business Metrics?

🏢
350+
Employees
📊
$510M
Total Funding
📊
31 programs, 29 targets
Drug Pipeline
📊
4
Clinical Stage Programs
📊
300
Patents Filed (2022)
📊
200
Peer-Reviewed Papers (2022)
📊
8-9
Preclinical Candidates (2021)

How Credible and Trustworthy Is Insilico Medicine?

88/100
Excellent

A well-established leader in AI drug discovery with significant funding, a clinical-stage pipeline, global presence, and recognized by Fortune and Nature.

BREAKDOWN
Product Maturity92/100
Company Stability90/100
Security & Compliance80/100
User Reviews75/100
Transparency85/100
Support Quality82/100
TRUST SIGNALS
First AI-discovered drug in Phase II trialsRecognized by Fortune as top 50 AI innovator (2024)Nature's top 50 biological research institutions (2025)$510M total funding from top VCs200+ peer-reviewed publications

What is the history of Insilico Medicine and its key milestones?

2014

Company Founded

Founded by Alex Zhavoronkov as an AI alternative to animal testing in pharmaceutical R&D.

2019

Internal Therapeutics Development

Transformed from services to develop proprietary therapeutics using AI platforms.

2021

Series C Funding

Received a $255 million megaround from investors including Warburg Pincus and Sequoia Capital and other investors.

2021

Fosun Pharma Partnership

Announced strategic partnership to access the Chinese market.

2022

Series D Funding & Expansion

Announced subsequent $60 million round raising and said it had received over $400 million in total investments and now has nine preclinical candidates.

2023

First AI Drug Clinical Trial

Began mid-stage human clinical trial on first fully AI-discovered and designed drug.

2024

HQ Relocation & Awards

Relocated headquarters to Boston; identified as number one of the top 50 AI innovators by Fortune.

2025

Nature Recognition

Identified as one of the 50 leading biological science research institutions.

What Are the Key Features of Insilico Medicine?

📊
Pharma.AI Platform
Generative AI platform which spans target discovery, molecular design and clinical trial predictions.
✨
PandaOmics
Engine for target discovery using multiomics data analysis and deep learning to discover novel disease targets.
✨
Chemistry42
Engine for de novo molecular design using generative adversarial networks to produce new drug candidates.
✨
InClinico
Engine for predicting outcomes from clinical trials to improve the design of clinical trials and increase the probability of successful outcomes.
✨
Frictionless Drug Discovery
Conduct parallel operations with 80 plus CROs and China-based discovery team to enhance speed and flexibility.
✨
Multi-Disease Targeting
Therapies that can be used for both treating a particular disease, and also for treating aging mechanisms.
✨
Accelerated Timelines
Reduce the length of time to convert a discovery to a preclinical candidate from 4.5 years to 18 months at 10 percent of the cost.

What Technology Stack and Infrastructure Does Insilico Medicine Use?

Infrastructure

Global operations with facilities in US, Hong Kong, China

Technologies

Deep LearningGenerative AIGANsBig Data AnalyticsGenomics

Integrations

CRO NetworksPharma PartnershipsMultiomics Databases

AI/ML Capabilities

Proprietary Pharma.AI platform with PandaOmics (target ID), Chemistry42 (molecular design), InClinico (clinical prediction) using deep learning, generative adversarial networks, and reinforcement learning

Based on company descriptions and technical publications

What Are the Best Use Cases for Insilico Medicine?

Pharmaceutical Companies
Use end-to-end AI platform to accelerate drug discovery pipelines from target identification to preclinical candidates and reduce the time by 75%, and the cost by 90%.
Biotech Startups
Gain access to AI-based target discovery and new molecular design without developing a high cost, in-house AI infrastructure.
Research Institutions
Use validated generative AI platforms to identify new targets for aging, fibrosis, oncology, and CNS diseases.
Cosmetics/Skincare Companies
Take advantage of the machine learning capabilities offered through Pharma.AI's division to find new compounds for anti-aging.
Small Molecule Drug Developers
Create novel molecules against newly identified targets that are generated using AI and predict clinical trials.
NOT FORIndividual Researchers
Not applicable – Enterprise level B2B platform that requires significant investment in infrastructure and partnership development.
NOT FORNon-Drug Therapeutics Developers
Applicable only in limited scope -- Exclusively focused on the use of AI for discovering drugs as small molecules.

How Much Does Insilico Medicine Cost and What Plans Are Available?

Pricing information with service tiers, costs, and details
☐Service$CostℹDetails🔗Source
Pharma.AI Platform AccessCustom enterprise contractAI-driven drug discovery services for target identification, molecule generation, and clinical predictionCompany prospectus and partnerships
R&D Collaboration ProgramsUpfront $32M + milestones up to $888M total (Servier deal)Multi-year oncology drug discovery partnerships with cost-sharingPR Newswire announcement
Drug Candidate LicensingMilestone payments (e.g., $5M Phase 1 dosing, $3M regulatory approval)Potential value exceeding $500M+ per program (Menarini deals)Longevity.Technology
AI Model Training (Gym)Custom quoteTraining AI models for biotech/pharma companies using Insilico's gym environmentFortune article
Pharma.AI Platform AccessCustom enterprise contract
AI-driven drug discovery services for target identification, molecule generation, and clinical prediction
Company prospectus and partnerships
R&D Collaboration ProgramsUpfront $32M + milestones up to $888M total (Servier deal)
Multi-year oncology drug discovery partnerships with cost-sharing
PR Newswire announcement
Drug Candidate LicensingMilestone payments (e.g., $5M Phase 1 dosing, $3M regulatory approval)
Potential value exceeding $500M+ per program (Menarini deals)
Longevity.Technology
AI Model Training (Gym)Custom quote
Training AI models for biotech/pharma companies using Insilico's gym environment
Fortune article

How Does Insilico Medicine Compare to Competitors?

FeatureInsilico MedicineExscientiaRecursion PharmaSchrödinger
Core FunctionalityGenerative AI for target ID, molecule design, clinical predictionAI small molecule designAI phenomics + chemistryPhysics-based modeling + AI
Pricing (starting price)Custom enterprise contracts ($32M+ upfront)Custom partnershipsCustom partnershipsSoftware licenses + services
Free tier availabilityNoNoNoAcademic licenses
Enterprise featuresFull automation, lab integrationEnd-to-end platformMassive data platformEnterprise deployment
API availabilityPharma.AI platform accessPlatform APIRecursion OS APILiveDesign platform
Integration countPartners: Servier, Menarini, Eli LillyGSK, BMS, SanofiBayer, RochePfizer, Takeda
Support optionsDedicated R&D partnershipsEnterprise supportEnterprise supportEnterprise support
Security certificationsN/A (biotech focus)Enterprise-gradeEnterprise-gradeEnterprise-grade
Core Functionality
Insilico MedicineGenerative AI for target ID, molecule design, clinical prediction
ExscientiaAI small molecule design
Recursion PharmaAI phenomics + chemistry
SchrödingerPhysics-based modeling + AI
Pricing (starting price)
Insilico MedicineCustom enterprise contracts ($32M+ upfront)
ExscientiaCustom partnerships
Recursion PharmaCustom partnerships
SchrödingerSoftware licenses + services
Free tier availability
Insilico MedicineNo
ExscientiaNo
Recursion PharmaNo
SchrödingerAcademic licenses
Enterprise features
Insilico MedicineFull automation, lab integration
ExscientiaEnd-to-end platform
Recursion PharmaMassive data platform
SchrödingerEnterprise deployment
API availability
Insilico MedicinePharma.AI platform access
ExscientiaPlatform API
Recursion PharmaRecursion OS API
SchrödingerLiveDesign platform
Integration count
Insilico MedicinePartners: Servier, Menarini, Eli Lilly
ExscientiaGSK, BMS, Sanofi
Recursion PharmaBayer, Roche
SchrödingerPfizer, Takeda
Support options
Insilico MedicineDedicated R&D partnerships
ExscientiaEnterprise support
Recursion PharmaEnterprise support
SchrödingerEnterprise support
Security certifications
Insilico MedicineN/A (biotech focus)
ExscientiaEnterprise-grade
Recursion PharmaEnterprise-grade
SchrödingerEnterprise-grade

How Does Insilico Medicine Compare to Competitors?

vs Exscientia

In contrast to Exscientia's focus on precision design, Insilico has developed generative AI across its entire pipeline (target to clinic) with 12-18-month preclinical timelines.

Insilico is positioned for broad AI transformation while Exscientia is positioned for precision chemistry optimization.

vs Recursion Pharmaceuticals

While both companies have gone public through IPO/SPAC, Insilico is demonstrating faster candidate nomination (20 programs 2021-2024), compared to Recursion which uses massive phenomic data (the largest private bio dataset) versus Insilico’s generative AI + automation.

Recursion is positioned for data-driven discovery, whereas Insilico is positioned for AI-generated novel molecules.

vs Generate Biomedicines

As opposed to Insilico's small molecules, Generate is developing protein therapeutics. Both companies have an AI-native approach; however, Generate has received significantly more venture capital funding ($700M+) than Insilico ($500M+); and Generate has demonstrated clinical proof-of-concept at a faster pace than Insilico.

Generate is positioned for biologics, whereas Insilico is positioned for small molecule fibrosis/oncology.

vs Schrödinger

Rather than being competitors, Schrödinger, which is a physics-first computational company (NASDAQ listed and profitable from software sales), is complementary to Insilico's pure AI approach and clinical-stage biotech model.

Schrödinger is positioned for physics modeling, whereas Insilico is positioned for end-to-end generative biology.

What are the strengths and limitations of Insilico Medicine?

Pros

  • Accelerate timelines -- 12-18 months from start to first-in-human preclinical candidate vs 4.5 years in the industry average Beginning of Text
  • Cost Efficiency — A complete preclinical program could be done for just $2 million, as opposed to the many hundred of millions of dollars for a complete preclinical program with a traditional company.
  • Clinical Validation — ISM has multiple phase one and two clinical stage assets, including Rentosertib (published in Nature Medicine).
  • Partnerships — ISM has partnerships that have been valued at over $1.8 billion; with Menarini (over $550 million) and Servier ($888 million); and is currently in talks with Eli Lilly.
  • Leadership In The Development Of Generative AI — Pharma.AI allows for the identification of targets through to the prediction of clinical outcomes.
  • Success of an IPO — $293 million was raised by ISM at a post-money valuation of $1.61 billion (HKEX 3696.HK).
  • Expertise in Oncology — ISM's compound ISM6331 (TEAD) and ISM3412 (MAT2A) are both in phase one clinical trials.

Cons

  • Ongoing Losses — Despite generating $85 million in revenue, ISM has generated a net loss of $17.4 million (as of 2024) and $18.9 million for the first six months of 2025.
  • An Enterprise-Only Model — No researcher or SME will ever have access to this technology, all researchers must sign a custom contract before they can use it.
  • Clinical Risk — ISM has early-stage assets that have yet to result in FDA-approved drugs, despite the advancement of its pipeline.
  • Volatility — The biotech sector is highly volatile and post-IPO performance of ISM will depend on achieving milestones and securing new partnerships.
  • Focus On Therapeutic Area — ISM has focused primarily on the development of drugs for the treatment of fibrosis and cancer, leaving little room for diversifying into other areas.
  • Exposure To China — ISM has conducted phase two clinical trials in China and may face regulatory and/or geopolitical risks associated with doing so.
  • Sales Cycles Are Long — ISM requires years to negotiate with large enterprises in order to secure a partnership contract, which contrasts sharply to the SaaS business model.

Who Is Insilico Medicine Best For?

Best For

  • Large pharmaceutical companies — Accelerate AI In Fibrosis/Oncology Pipelines. Successful with Servier, Menarini, Lilly partnerships.
  • Oncology R&D teams — ISM6331, ISM3412 in Phase I + robust AI oncology platform. Multiple partnered programs.
  • Companies seeking novel targets — Target ID + preclinical in 18 months (e.g., IPF TNIK example). Excellent target discovery capabilities in Pharma.AI
  • Biotechs lacking computational expertise — Full-stack Pharma.AI greatly reduces the need to establish in-house AI/ML drug discovery teams.
  • Investors in AI biotech — Public (HKEX), clinical assets, $500M+ VC backing, substantial milestone-driven cash flow.

Not Suitable For

  • Academic researchers — Only enterprise pricing model available. Consider using open-source tools such as AlphaFold instead.
  • Small biotech startups (<50 employees) — Unrealistic $32M+ up-front commitment expectations. Consider using contract research organizations instead.
  • Non-oncology/fibrosis focus — Concentration of pipeline risk. Very limited validated experience beyond main areas of focus.
  • Companies needing immediate commercial drugs — Clinical Stage Early — All ISM clinical-stage assets are either in phase one or phase two clinical trials.

Are There Usage Limits or Geographic Restrictions for Insilico Medicine?

Target Therapeutic Areas
Primarily fibrosis, oncology, immunology. Limited experience outside core areas
Client Scale
Enterprise pharma/biotech partnerships only. No individual/SMB access
Preclinical Timeline
12-18 months per program (20 PCCs 2021-2024)
Deal Structure
$32M+ upfront + milestones for collaborations
Geographic Exposure
HQ Hong Kong, trials in China, global partnerships
Clinical Stage
Phase I/II maximum. No approved therapeutics
Synthetic Scale
60-200 molecules per program (AI efficiency)

Is Insilico Medicine Secure and Compliant?

Clinical Data HandlingMeets international standards for Phase I/II trials (China + global sites). Nature Medicine publication standards
IP ProtectionMultiple AI-designed molecules protected. HKEX-listed with robust patent portfolio
Data PrivacyGlobal partnerships comply with partner pharma requirements (Servier, Menarini EU/US)
AI Model SecurityProprietary Pharma.AI platform. No public disclosure of training data/methodology
Financial TransparencyHKEX (3696.HK) regulated. Full prospectus disclosure of revenue/losses/partnerships
Partnership GovernanceCost-sharing agreements with cost-sharing. Clear milestone structures

What Customer Support Options Does Insilico Medicine Offer?

Channels
Assigned to enterprise partners (Servier, Menarini)Joint project management for milestone deliveryHKEX public company requirementsVia website contact form
Hours
Business hours across global offices (Hong Kong, US, Europe)
Response Time
Enterprise partner-specific SLAs within collaboration agreements
Satisfaction
N/A - B2B enterprise model, no public review scores
Specialized
Scientific collaboration support for AI drug discovery programs
Business Tier
Dedicated R&D teams for multi-million dollar partnerships
Support Limitations
•Support limited to signed enterprise partners
•No self-service or free tier support
•Academic/researcher support unavailable

What APIs and Integrations Does Insilico Medicine Support?

API Type
Python and API access supported for Nach01 model inference and fine-tuning
Cloud Deployment
Available on AWS Marketplace with Amazon SageMaker integration for managed ML deployment and scaling
Platform Integration
Nach01 integrates with Microsoft Discovery platform on Azure for orchestrated drug discovery workflows, enabling composition of AI-driven workflows with other computational tools and data sources
Model Access
Inference and fine-tuning available; can be fine-tuned on proprietary datasets and deployed directly within AWS environments
Use Cases
Molecular generation, retrosynthesis, ADMET property prediction, activity prediction, quantum-level calculations, hit discovery, and lead optimization workflows

What Are Common Questions About Insilico Medicine?

Nach01 is a chemistry-based generative multimodal foundation model designed to learn both structurally and spatially and to accomplish hundreds of various chemistry-related tasks, such as the synthesis of molecules, prediction of molecular features and structure, and the generation of molecules in 2D and 3D formats. Additionally, it has the capability to calculate the quantum mechanical level characteristics of molecules (activity and ADMET properties).

The Insilico AI platform, which includes Nach01, functions similarly to an 'oracle' providing guidance during the process of generating new molecules, supporting machine learning-based reinforcement learning pipelines, and increasing the efficiency of validating experimental results. The platform can use aging biology to identify potential disease targets, generate tens-of-thousands of novel compounds at a time, and integrate other AI models throughout the entire drug discovery workflow.

Yes. Nach01 is available for use on AWS Marketplace with SageMaker integration and can be used in conjunction with Microsoft Discovery on Azure. The models are accessible via Python and/or API and can be fine-tuned using a partner’s proprietary datasets.

DORA (Draft Outline Research Assistant) is an AI-powered tool that assists users in creating drafts of academic papers and producing biomedical documentation. The tool utilizes AI Agents with retrieval-augmented generation from scientific databases that have been integrated with Insilico’s Data Warehouse to create research documents with citations and evidence from multiple sources.

Insilico Medicine prioritizes IT Governance and Security with compliance frameworks and secure cloud technologies. The Company provides data protection for its partners by combining IT Governance with secure cloud infrastructure.

Insilico Medicine utilizes generative AI to transform each aspect of the drug discovery pipeline from identifying molecular targets through generating and optimizing novel compounds. Unlike traditional methods that require manual screening, Insilico’s AI can rapidly search chemical space and generate novel scaffold structures while predicting the physical and chemical properties of generated molecules at scale.

01, the Nach model is deployable in the cloud with AWS via SageMaker and can be integrated with Microsoft Discovery to work with Azure. There are several cloud-based deployment options identified in search results; however, to confirm the availability of on-site deployments, you would need to contact Insilico directly.

Insilico has developed Generative Biologics for the generation and optimization of biologics, Precious3GPT for multi-omics and aging-associated target prediction, DORA for automated research document drafting and LEGION for searching chemical space while protecting intellectual property by strategically filing patents.

Is Insilico Medicine Worth It?

As a highly integrated, technically capable AI system for computational drug discovery, Insilico Medicine provides a powerful and well-integrated platform for performing all aspects of computational drug discovery, including the generation of molecules, as well as generating research documents. This platform is a comprehensive ecosystem that was built to support the needs of modern pharmaceutical R&D. Strong backing from its partnership with both AWS and Microsoft and its position as a large-scale enterprise platform demonstrate the company's serious commitment to the drug discovery industry.

Recommended For

  • Pharmaceutical and biotechnology companies with large-scale computational chemistry teams.
  • CROs providing AI-enhanced drug discovery services.
  • Academic research institutions with large-scale computational chemistry programs.
  • Companies looking for a complete workflow of AI-driven drug discovery from target to optimized molecule.
  • Organizations using Microsoft Azure or AWS cloud infrastructure.

!
Use With Caution

  • Small, early stage biotech companies with very little or no computational chemistry knowledge/experience -- will likely require a great deal of training and/or education.
  • Companies with specific on-site requirements -- the platform is cloud-native on AWS and Azure.
  • Companies that want to integrate wet-lab experiments into their computational workflow -- this will require at least some hybrid wet-dry expertise.
  • Companies that want to see results in real time -- generative modeling/prediction may need to be optimized for speed.

Not Recommended For

  • Insilico Medicine is ideal for small biotech companies with very limited computer budget — they will have to pay extra for use of the enterprise cloud and for access to models.
  • Traditional QSAR or docking-only workflow companies — special tools would be more suitable for these types of companies.
  • Simple molecule library search — too much overhead for basic compound screening.
Expert's Conclusion

Insilico Medicine will be best for large, established pharmaceutical organizations with the necessary experience and resources for using the Cloud for the purpose of being able to take advantage of an AI native drug discovery platform which will enable them to significantly decrease their drug discovery timelines and produce substantially larger numbers of new compounds than before.

Best For
Pharmaceutical and biotechnology companies with large-scale computational chemistry teams.CROs providing AI-enhanced drug discovery services.Academic research institutions with large-scale computational chemistry programs.

What do expert reviews and research say about Insilico Medicine?

Key Findings

Insilico Medicine provides a mature AI-based drug discovery platform, the flagship product being Nach01, a multimodal generative chemistry model, that is currently available on AWS Marketplace and can be integrated into Microsoft Discovery on Azure. The company has demonstrated substantial technical capability regarding both molecular generation and property predictions as well as automation of research — it has also shown that it has substantial market positioning for the enterprise and substantial potential for adoption by the industry as evidenced by the multiple partnerships the company has formed with several different organizations.

Data Quality

Good - comprehensive information from official Insilico website, AWS Marketplace announcements, Microsoft technical documentation, and company blog posts. Information covers product capabilities, deployment options, and integration frameworks. Pricing details and specific customer deployments are not publicly disclosed.

Risk Factors

!
Specific details about pricing and commercial terms for the services provided by Insilico Medicine were not publicly disclosed.
!
Very little data was found regarding specific case studies from customers or specific Return On Investment metrics.
!
Enterprise-level platform requires a substantial investment in cloud infrastructure.
!
A competitive landscape exists for AI drug discovery platforms.
!
Information related to regulatory pathways and FDA approval status of compounds generated by the company's process were not reported in the available public domain.
Last updated: February 2026

What Additional Information Is Available for Insilico Medicine?

Founder & Leadership

Insilico Medicine was founded by Dr. Alex Zhavoronkov, who is the current CEO and indicates that Insilico Medicine is developing pharmaceutical AI systems capable of generating large amounts of novel chemical matter at scale. The company states that the mission of Insilico Medicine is to extend human healthspan and productive longevity via the application of AI technologies to transform drug discovery.

Platform Integration Ecosystem

Insilico Medicine has partnered strategically with cloud computing giants. For example, Nach01 is now available for deployment on AWS Marketplace via SageMaker and can be used to create coordinated R&D workflows utilizing Microsoft Discovery on Azure; this allows companies to deploy the platform in an enterprise environment using either of two different cloud computing infrastructures.

Product Suite Breadth

In addition to Nach01, Insilico also provides Generative Biologics to help optimize peptides and proteins; DORA as an automated tool to streamline research documents, with automatic citation integration; Precious3GPT to analyze multi-omics data; and LEGION to strategically generate new compounds, protect them using pro-active patenting strategies, and develop intellectual property protection.

Research Applications

Insilico’s platform is able to address several different stages of pharmaceutical discovery: target identification; hit generation; ADMET prediction; lead optimization; and molecular property modeling. Insilico’s platform can accelerate a Design-Make-Test-Analyze (DMTA) cycle through AI integration.

Cloud Infrastructure & Security

Insilico has emphasized IT governance and compliance frameworks in the use of secure cloud technologies. Using enterprise-wide deployments such as AWS SageMaker and Azure ML Workspace will provide scalable compute orchestration with elastic infrastructure management.

Research Automation

DORA includes retrieval-augmented generation from scientific databases and Insilico’s proprietary data warehouse that enables automated hypothesis generation, target discovery analysis, clinical trial analysis, and bioinformatics workflows with integrated citations.

Intellectual Property Strategy

LEGION, Insilico’s workflow, includes two objectives: generating novel compounds and at the same time developing intellectual property protection for those compounds through strategic patenting approaches. LEGION addresses the challenges associated with the competitive landscape of rapid patenting by competitors.

What Are the Best Alternatives to Insilico Medicine?

  • •
    Schrodinger: An established computational chemistry platform that utilizes physics-based molecular modeling, docking, and simulation tools. Less AI-native than other platforms, and more mature with decades of deployment experience in pharma. A good option for organizations that prefer structure-based drug design workflows, and have a strong preference for traditional computational chemistry that they know works well. (SCHRODINGER.COM)
  • •
    DeepMind AlphaFold (Isomorphic Labs partnership): Pharmaceutical workflow-integrated capabilities for AI-assisted structure prediction and protein design. Good for structural predictions and protein designs, however may be too specific for a complete drug discovery pipeline. Good for companies that focus on biologics and/or utilize AI-assisted protein structure prediction. (isomorphiclabs.com)
  • •
    BenevolentAI: An end-to-end AI-based drug discovery system with knowledge graphs, target identification, and compound generation. Competitive with Insilico in terms of breadth, but uses a different technical strategy. Good for Pharma that is looking for an AI-based native platform with a history of clinical success.
  • •
    Exscientia: A fully AI-based drug discovery platform utilizing generative models and machine learning for both small molecule and biologic drugs. Very good at optimizing designs and has several FDA-approved compounds in their pipeline. Good for companies that want to have proven AI-generated molecules as well as preclinical-to-clinical development paths.
  • •
    Atomwise: An AI-based virtual screening and molecular design platform using physics-informed deep learning. More specialized to hit discovery and lead optimization phases. Less expensive than all-encompassing platforms. Good for companies that need a focused molecular design capability without integrating the entire drug discovery pipeline.
  • •
    Recursion Pharmaceuticals: Phenotypic screening combined with AI/ML to identify and validate potential drug targets. The company differs by including experimental data as part of their process versus other purely computational approaches. Good for companies that want to integrate AI with high-throughput experimental validation.

Scientific ROI Metrics

30 months
Time to Phase 1 Clinical Trials
12-18 months
Time to Preclinical Candidate (PCC)
1/10 of traditional cost
Cost Reduction vs Traditional
60-200 molecules
Molecules Synthesized per Program
High (20+ candidates 2021-2024) candidates nominated
Preclinical Success Rate

Core Discovery Capabilities

Target Discovery & Prioritization

Rapidly identifies novel disease targets from multi-omics data using AI

Generative Chemistry

De novo design of drug candidates using GANs, transformers, and deep learning

End-to-End Preclinical Workflow

A fully integrated platform from target ID through candidate nomination to clinical prediction

Clinical Trial Prediction

Predicts trial outcome results to help select candidate drugs

Molecular Binding Prediction

Uses AI models to predict target-compound binding affinity and drug-likeness

Multi-Indication Drug Design

Has supported fibrosis, oncology, immunology, pain, and obesity applications

ML Architecture & Computational Specifications

Core AI Platform
Pharma.AI (PandaOmics + Chemistry42 + InClinico)
Generative Models
GANs, Transformer models, diffusion models, deep neural networks
Training Data Scale
Millions of data samples across biology and chemistry
Target Discovery Throughput
Rapid identification (20 targets validated from initial analysis)
Candidate Generation Speed
Days for novel compound design; 80 molecules designed for IPF program
End-to-End Timeline
18 months target-to-candidate; 30 months to Phase 1
Hardware Acceleration
NVIDIA GPU integration including BioNeMo framework
Validation Track Record
Phase 2 clinical trials achieved; 20+ preclinical candidates 2021-2024
Molecular Formats
SMILES and standard cheminformatics formats supported
Deployment Model
Licensed platform to pharma partners; cloud-enabled

What Primary Use Cases Does Insilico Medicine Offer?

Novel Target Identification (Fibrosis, Oncology)Generative AI Molecule Design (De Novo)End-to-End Preclinical Candidate NominationClinical Trial Success PredictionIdiopathic Pulmonary Fibrosis (Phase 2)Kidney Fibrosis Drug CandidatesImmunotherapy Compound DesignMulti-Therapeutic Area Pipeline (20+ programs)Pharma Partnership Target Optimization

What Is Insilico Medicine's Regulatory Compliance Requirements Status?

Phase II Clinical Trials AchievedINS018_055 in Phase II for IPF
Phase I Clinical Validation30 months from start to IND
Preclinical Candidate Success20+ PCCs nominated 2021-2024
Major Pharma PartnershipsLilly, Sanofi, Exelixis, Fosun deals
Peer-Reviewed ValidationNature Biotechnology publications
Target Novelty ValidationNovel intracellular targets confirmed
Industrial Scale ValidationLicensed to multiple pharma companies
In Vivo Experimental Validation21-day DDR1 prediction confirmed
Platform ReproducibilitySuccess replicated across 20+ programs
IP Protection StrategyProprietary platform licensing model

Integration & Workflow Capabilities

End-to-End AI Pipeline

Integration of all three components: Target Discovery, Chemistry Design, Clinical Prediction to create a seamless process.

Pharma Partnership Integration

Client programs utilizing licensed platform deployments for Lilly’s collaboration.

Multi-Omics Data Integration

PandaOmics analyzes multiple forms of biological data to help prioritize targets.

Automated Synthesis Planning

Chemistry42 produces molecule designs that can be synthesized (60 – 200 per program).

Iterative Optimization Loops

Generative AI enables rapid design-synthesis-test cycles.

NVIDIA BioNeMo Integration

Foundation Models using GPU’s are being used as an accelerator in drug discovery.

Industrial Workflow Scale

Over 20 programs have been completed; ready for deployment with Enterprise Pharma clients.

AI Drug Discovery Platform Performance Benchmarks

Performance MetricInsilico Pharma.AITraditional MethodImprovement Factor
Time to Preclinical Candidate12-18 months3-6 years4-6x Faster
Time to Phase 130 months6+ years2.5x Faster
Project Cost1/10 traditional$400M+10x Cost Reduction
Molecules Synthesized60-200 per programThousands95% Reduction
Candidates Nominated20+ (2021-2024)1-2 per multi-year program10x+ Output
Clinical Trial ProgressionPhase 2 achievedYears of preclinical delayHistorical first
Target NoveltyNovel intracellular targetsKnown targets typicallyFirst-in-class potential

AI Drug Discovery Platform Evaluation Priority Matrix

Priority LevelEvaluation CategoryInsilico Medicine Assessment
1 - CRITICALScientific Impact & ValidationPhase 2 clinical trial achieved; 20+ preclinical candidates; Nature Biotechnology validation
1 - CRITICALROI Metrics & Timeline Reduction30 months to Phase 1 (vs 6+ years); 10x cost reduction; 12-18 month PCC timeline
2 - HIGHML Explainability & InterpretabilityIndustrial validation through clinical progression; peer-reviewed methodology
2 - HIGHR&D Integration & WorkflowEnd-to-end Pharma.AI platform; Lilly/Sanofi partnerships; enterprise licensing
3 - MEDIUMComputational ScalabilityNVIDIA GPU/BioNeMo integration; 20+ programs scaled successfully
3 - MEDIUMRegulatory & Compliance ReadinessPhase II trials demonstrate regulatory pathway success
4 - MEDIUMData Security & IP ProtectionProprietary platform licensing model protects client IP

Expert Reviews

📝

No reviews yet

Be the first to review Insilico Medicine!

Write a Review

Similar Products

PostEra
postera.ai
BenevolentAI
benevolent.ai
Recursion Pharmaceuticals
recursion.com